Definitive Healthcare

Overview

Definitive Healthcare is a healthcare commercial intelligence platform that turns provider, claims, and KOL data into targeting and market insight for life-sciences commercial teams. Founded in 2011 by Jason Krantz, it now serves 2,500+ customers including leading pharma, biotech, and medtech companies through the Atlas reference dataset, PatientFinder cohort tooling, and all-payor claims analytics.

Definitive Healthcare is not a hub services operator, a regulatory-grade RWE platform, or a specialty-pharmacy data integrator; it is a commercial-intelligence layer that informs upstream targeting, territory design, and market sizing decisions. The buyer is typically a commercial operations, sales analytics, or KOL strategy team rather than a market-access or medical-affairs evidence team.

Platform Capability Model

The framework below standardizes how Rx Almanac evaluates data-technology-platforms capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Definitive Healthcare is evaluated as healthcare commercial intelligence platform that turns provider, claims, and KOL data into targeting and market insight for life-sciences commercial teams.

Capability	Buyer should compare	Definitive Healthcare readout
Data aggregation and interoperability	Claims, EHR, CRM, pharmacy, provider, payer, and FHIR/API connectivity with normalization and identity resolution.	Major data foundation. Atlas integrates 16M+ HCPs, 330K+ organizations, all-payor claims, and KOL profiles into a single reference and analytics environment.
Commercial analytics and patient finding	Targeting, segmentation, patient finding, provider analytics, referral leakage, and opportunity sizing.	Major analytics use case. Provider analytics, referral mapping, and PatientFinder cohort building are the primary differentiation against narrower claims-only vendors.
Workflow automation and CRM integration	Case workflows, field workflows, CRM, task automation, document handling, and operational queue management.	Workflow layer. Self-service territory and call-plan workflows feed downstream CRM systems; not a CRM owner.
Provider, payer, and pharmacy network connectivity	Network reach across HCPs, payers, pharmacies, labs, health systems, and transaction endpoints.	Major network reach. All-payor claims plus provider affiliation depth support commercial workflows; pharmacy and payer transaction integration is not the use case.
AI, NLP, and unstructured data extraction	Conversation intelligence, document AI, NLP extraction, predictive models, and model monitoring.	Confirm automation workflow in the RFP. AI-enabled capabilities exist; confirm what is production-grade for the buyer’s specific use case versus marketing positioning.
Security, compliance, and governance	HIPAA, SOC2, data-use controls, auditability, consent, privacy, and regulated-workflow safeguards.	Confirm governance control in the RFP. Public marketing surfaces are commercial-intelligence first; confirm permitted-use, data-rights, and audit terms by product.
Reporting, dashboards, and data delivery	Dashboards, exports, APIs, scheduled reporting, and downstream feeds to analytics or operating teams.	Major reporting layer. Snowflake and Databricks data integrations plus LiveRamp and Bombora partnerships extend delivery into customer data and activation environments.

Buyer Fit

• Best-fit use case: Use when commercial operations needs unified provider, claims, and KOL intelligence for targeting, territory design, account planning, or KOL strategy.
• Best-fit buyers: Commercial operations, sales analytics, brand analytics, market analytics, and KOL strategy teams at pharma, biotech, and medtech manufacturers; also providers, health systems, and payer commercial teams.
• Less ideal fit: Regulatory or HEOR evidence work where decision-grade methodology is required; specialty patient-journey or hub data; outsourced fieldwork or services.
• Commercial fit: Subscription; assume an RFP-led scope with seats, data product coverage, integration pattern, and activation rights defined in the SOW.
• Commercial diligence: Confirm Atlas coverage depth in the target therapeutic area, claims refresh cadence, KOL profile completeness, Snowflake/Databricks delivery, and any ad-tech / activation permissions the manufacturer wants.

Differentiators

• Atlas dataset breadth: 16M+ HCPs, 330K+ organizations, and all-payor claims integrated with KOL intelligence in one reference layer.
• PatientFinder cohorting: Real-time custom patient cohorts by disease state, tuned for commercial use cases rather than regulatory-grade methodology.
• KOL landscape mapping: 13M+ expert profiles connect prescribing behavior, affiliations, and influence networks for medical-affairs adjacency.
• Snowflake and Databricks delivery: Native integrations let customers operate Definitive data inside existing cloud-data environments rather than only in the Definitive UI.
• Activation ecosystem: LiveRamp marketplace inclusion, Bombora “Curated Ecosystem Audiences,” and 30+ agency relationships extend Definitive data into managed media and audience activation workflows.

RFP Questions

• Which Atlas, claims, KOL, and PatientFinder modules are included, and which require separate licensing?
• What is the claims data refresh cadence, source mix, and lag by payer segment?
• How does Definitive integrate with the manufacturer’s existing CRM, Snowflake, Databricks, or data-lake environments?
• What KOL profiling methodology, source coverage, and refresh cadence support medical-affairs adjacent work?
• Which audience-activation, LiveRamp, and agency-channel rights are included or restricted under the proposed contract?
• What references exist for the specific therapeutic area, geography, and use case the buyer is evaluating?
• How are permitted uses, derivative-work rights, and downstream-sharing terms governed?

Recent Activity

• 2026-05 - Current Definitive materials add HubSpot and Salesforce AgentExchange workflow signals, AI-search positioning, and a FY2025 active-subscription anchor that buyers should reconcile against older customer-count claims.

• 2026-Q1: Guided $220-226M for 2026 (-6 to -9% year over year), continuing a public-market reset alongside go-to-market changes.

• 2025-Q3: Bombora named inaugural data provider for “Curated Ecosystem Audiences,” matching reference and affiliation data with behavioral signals.

• 2025-Q3: LiveRamp “always-on” GTM partnership announced; Definitive proprietary data made available in the LiveRamp marketplace for self-serve privacy-safe activation.

• 2025-early 2026: 30+ healthcare advertising agencies signed to embed Definitive intelligence directly into managed media campaigns.

• 2024-06: CEO transition with Kevin Coop (formerly DailyPay CEO and Dun & Bradstreet North America President) appointed CEO.